Sold as Povan. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 2 applications for Pyrvinium pamoate (sold as Povan), with 0 new uses approved and 0 published complete response letters.
| โ | PovanNDA 11964 | Parke-Davis | 0 | Discontinued |
| โ | PovanNDA 12485 | Parke-Davis | 0 | Discontinued |
| Use of Pyrvinium to Reverse Stomach Precancerous ConditionsSTOMACH NEOPLASM ยท National University Hospital, Singapore | Phase 2 | Not yet recruiting | Jan 17, 2025 |
| REVerse Intestinal Metaplasia in the Stomach (REVISE)Gastric Intestinal Metaplasia, Gastric Precancer ยท Katherine Garman | Phase 2 | Recruiting | Sep 19, 2024 |
| A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic CancerResectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8 ยท Thomas Jefferson University | Phase 1 | Active, not recruiting | Sep 24, 2021 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA